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Introduction 
Blau syndrome is a rare, potentially debilitating, dominantly inherited prototypic 
autoinflammatory disease1. The Blau phenotype results from mutations in or near the 
nucleotide oligomerization domain of the NOD2 pattern recognition receptor. A typical 
clinical triad of arthritis, dermatitis and uveitis is characteristic. However, systemic 
features including vasculitis and involvement of various organ systems have become 
widely recognized2, 3.  Whilst ocular involvement in Blau syndrome is a predominant 
feature, to date the extent of involvement or severity of inflammation has not been 
prospectively evaluated in a substantial number of patients. Following the initial 
report by Edward Blau where three members of the family displayed persistent 
bilateral granulomatous iritis, with or without posterior segment inflammation requiring 
oral corticosteroid therapy, further reports have documented a wide-ranging ocular 
involvement4.   For example, the frequency of bilateral panuveitis ranged from 33 to 
94%, often associated with chronic multifocal choroiditis1, 5, 6. A more recent detailed 
study of 17 eyes displayed optic nerve head involvement as a consistent finding7.  
Limitations of reports to date include small case series or studies,  lack of longitudinal 
data including outcome and severity and retrospective data analysis. Therefore, 
many aspects of the disease, including ocular involvement and disease evolution 
remain elusive2.  
The data presented here are derived from analysis of 50 Blau patients included in an 
on-going  5-year multicenter, prospective interventional case series aimed at 
investigating the evolution of clinical manifestations of Blau syndrome2. Here we 
present a cross-sectional analysis of the Blau ocular phenotype of 50 patients at 
baseline study visit. We also present interim data of follow-up clinical details of 
patients (30 patients at year 1, 19 patients at year 2 and 13 patients at year 3) to 
document and present disease progression and cumulative ocular damage.  
Our study describes the high frequency and severity of Blau uveitis and highlights the 
need for close ophthalmologic surveillance as well as a search for more effective 
therapies. 
 
 
Patients and methods 
 
Patient inclusion 
Ophthalmological data were collected from 50 Blau patients included in a 5-year 
multicenter, prospective interventional case series on articular, functional, 
ophthalmological, therapeutic and radiological data2. Investigators who participated in 
the Paediatric Granulomatous Arthritis International Registry and members of 
paediatric rheumatology societies were invited to join in this prospective study. Ethics 
committee or institutional review board approval was obtained at the coordinating 
centre (University of Leuven) and all participating sites (25 sites, 1-7 patients per 
site). All patients with a clinical diagnosis of Blau syndrome based on any 
(combination of) Blau clinical triad features, and proven NOD2 mutations from each 
site were included after written informed consent had been obtained. One patient 
was later excluded because his genetic NOD2 variant was not considered pathogenic 
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on secondary analysis. Patient inclusion commenced in 2011. The recruitment target 
of 50 patients was completed in February 2016 and for each patient data capture 
continues annually for a total of 5 years. The results presented in this report include 
baseline data from 50 patients at 25 centers worldwide, and follow-up data from 
patients followed for 1, 2 and 3 years at the time of completed enrollment. At that 
time, there were insufficient data to report years 4 and 5 of follow-up. 
 
Data Capture 
A standardized ophthalmologic data collection form was used by the ophthalmologist 
at the participating centers (supplemental material on AJO.com). At baseline clinic 
visit, historical data were also recorded to capture date including onset of eye 
involvement and where possible detail of classification of uveitis, ocular complications 
and previous treatments (medical and/or surgical). At each visit, the ophthalmologist 
recorded uveitis laterality, graded uveitis activity based on the anatomical SUN 
classification and reported uveitis descriptors as developed by the SUN working 
group (onset, duration, course)8. Current treatment (topical and systemic) was 
recorded. Best corrected visual acuity was measured with the ETDRS chart (adults) 
or Kay Pictures (children) for distance and near. Visual acuity data per eye were 
evaluated against key thresholds, as defined by the SUN working group8. Visual 
impairment was defined according to the WHO guidelines (best-corrected visual 
acuity in best eye) 9. No or mild visual impairment was defined by a logMAR from 0.0-
0.5 (Snellen 20/20 – 20/60), moderate visual impairment from 0.5-0.9 (20/60 – 
20/200), severe visual impairment from 0.9-1.3 (20/200 – 20/400), and blindness 
from >1.3 (>20/400). Anterior segment cells and flare were recorded per SUN 
classification. Active anterior chamber inflammation was defined as grade 0.5+ or 
more. Vitreous haze was noted and visibility recorded based on the Nussenblatt 
chart10. Fundal findings were recorded, and lesions were characterized as either 
active or inactive (scars) based on the clinical judgment (qualitative) by the treating 
ophthalmologist. Furthermore, sequelae of both anterior and posterior segment 
inflammation and  intra-ocular pressure were recorded. Elevated intra-ocular 
pressure was defined as eye pressure greater than 24 mmHg on applanation 
tonometry and/or treatment with glaucoma medication8. Finally, the local 
ophthalmologist was asked to give an overall subjective grading of eye disease 
severity (mild, moderate or severe) based on their own judgment and taking into 
consideration visual acuity, structural and other complications, and treatment.  
 
Statistics 
Descriptive statistics were used for demographic and clinical findings. To determine 
statistical significance with respect to parameters of inflammation, Fisher’s exact test 
was employed. The influence of disease duration on severity of uveitis, was tested 
using logistic regression. Differences in uveitis severity in relation to gender or 
familial occurrence were analysed using chi-squared test. Visual acuity data were 
analysed using Kaplan-Meier curve for best and worst eye separately. Differences in 
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rate of visual acuity loss between mutations were tested with log Rank test. Analyses 
were performed with STATISTICA v12 software (Statsoft, Inc, Tulsa, OK).  
 
 
Results 
 
Demographics and genetics  
Fifty patients from 25 centres across Europe, the United States, Canada, Latin-
America and Asia were included in the study. Eighteen patients carried heterozygous 
p.R334W NOD2 mutations, 13 heterozygous p.R334Q mutations, 4 heterozygous 
p.R587C mutations and the remaining 14 patients a variety of different NOD2 
mutations (T605P, M513A, M514T, M513T, G481D, G464W, E383K, E383D + 
D390V, Y563S, C495Y and A755V). One patient was excluded upon retesting of his 
genetic sample (see Methods section). Data from 49 patients (24 female, 25 male) 
were analysed. Table 1 gives an overview of patient and ocular clinical 
characteristics at baseline. In this case series, 31 patients (63%) manifested all three 
typical features of Blau syndrome. No patients had isolated uveitis, while 4 patients 
(8%) showed only skin manifestations and 4 other patients (8%) had only joint 
manifestations. A combination of skin and joint involvement was seen in 3 patients 
(6%), skin and eye involvement in 3 patients (6%), joint and eye involvement in 4 
patients (8%). The median age at baseline was 205 months (range 21 – 667), 27 
patients (55%) were younger than 18 years of age. The median age at onset of eye 
involvement was 60 months (range 6 -575). Median age at onset of skin and joint 
involvement was 15 (range 2-276) and 24 months (range 3 – 612), preceding eye 
involvement by a median of 45 and 36 months respectively. The median duration of 
eye disease at baseline visit was 145 months, while median skin and joint 
involvement at baseline was 190 and 181 months. Thirty patients had the sporadic 
form of the disease, while 20 patients belonged to 9 distinct Blau pedigrees. There 
was no difference in occurrence of panuveitis between male and female patients 
(Chi-squared test, p=0.6) or between sporadic and familial cases (Chi-squared test, 
p=0.3).   
 
Ocular involvement   
Of the 38 patients with ocular involvement at baseline study visit, 37 (97%) had 
bilateral uveitis. Of these 75 affected eyes, 22 presented with anterior uveitis only 
(29%), while 38 had panuveitis (51%). In the remaining 15 eyes, a combination of 
anterior and/or intermediate or posterior uveitis was diagnosed. In total, the anterior 
segment was involved in 99% of eyes, the intermediate and posterior segments in 
65% and 56% respectively. Follow up data for 6 of 11 patients with no ocular 
involvement at baseline, showed no development of uveitis after 1 year (1 patient), 2 
years (1 patient) and 3 years (4 patients) respectively. 
Logistic regression analysis showed that duration of eye disease is an important 
factor to predict the presence of panuveitis in the patient, with a longer duration being 
associated with the presence of panuveitis (p=0.01). 
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At the time of this report (February 2016) follow-up data were available for 47, 30 and 
18 affected eyes at year 1, 2 and 3 respectively.  
 
Ocular Inflammation and ocular complications 
At baseline, optic disc changes were described in 22 eyes (29%), comprising pallor in 
9 eyes (12%), peripapillary nodules in 9 eyes (12%) and edema in 4 eyes (5%). 
Macular edema was noted in 8 eyes (11%), only occurring in eyes presenting with 
panuveitis. The most commonly described fundus change were multifocal 
chorioretinal lesions in 29 eyes (39%). Chorioretinal disease was active in 4 out of 75 
eyes at baseline visit (5%).  No active vasculitis was described (Table 2). Figure 1 
shows typical ophthalmological features observed in our patient population. 
We undertook an interim analysis as documented in Figure 2 to demonstrate our 
early findings with respect to evolution of inflammatory parameters from baseline 
over a 3-year period. Despite all patients receiving prolonged topical and systemic 
treatment (at individual physicians discretion), there was no significant decrease of 
inflammatory activity at yearly visits (Fisher’s Exact test). Table 2 shows the 
prevalence of optic disc and chorioretinal changes at follow-up visits. Macular edema 
was noted in 8 – 16% of eyes during follow-up.  Chorioretinal lesions remained the 
commonest abnormality and recorded in 43 eyes (50%). At follow-up, active 
choroiditis was noted in 5 eyes (10%).  
Uveitis complications in the anterior segment were also common. Band keratopathy 
was noted in 16 patients (21%), posterior synechiae in 34 patients (45%) and 
cataract in 41 patients (55%) at baseline visit (table 2). With follow-up, the prevalence 
of these complications remained unchanged.  At baseline visit, 19 eyes (25%) had 
elevated intra-ocular pressure. During follow-up, 10, 5 and 3 patients (9%, 17% and 
17%) at years 1,2, and 3 respectively were reported to have elevated intra-ocular 
pressure.  
 
Medication 
At baseline visit, 56 out of 75 eyes were on topical corticosteroids (75%). Topical 
anti-glaucoma medication was used in 12 eyes (16%) and 10 eyes were on mydriatic 
agents to prevent the formation of posterior synechiae (13%). Thirty-seven of the 38 
patients with ocular involvement, were treated with systemic medication with 68% 
receiving a combination of systemic corticosteroids with immunosuppressive drugs 
and/or biologicals. Within these combinations, systemic corticosteroids were the most 
commonly used (26 patients), followed by methotrexate (18 patients), adalimumab 
(17 patients), infliximab (5 patients), mycophenolate mofetil (3 patients), thalidomide 
(2 patients) or canakinumab (1 patient). Choice of immunosuppressants differed 
among the participating centers, and therefore efficacy was difficult to ascertain. 
Eight patients were reported to have insufficient disease control with methotrexate. 
Six patients had insufficient disease control with etanercept. Two patients 
experienced an adverse drug reaction to infliximab infusion, leading to 
discontinuation of the drug. No other major side-effects were reported.   
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Visual acuity 
Data on visual acuity were available for 66 eyes at baseline and for 40, 28 and 16 
eyes for years 1, 2 and 3 respectively. Table 3 shows data on visual acuity at 
baseline visit and during follow-up.  Using WHO criteria for visual impairment, 21% of 
patients experienced moderate visual impairment at baseline visit. 
Determining visual acuity loss during follow-up, when assessing the best eye, there 
was a trend over the course of three years for further visual loss. By year 3, there 
was a cumulative decrease in visual acuity of the best eye of 33% (Kaplan-Meier 
regression analysis; Figure 3).  
When we compared the rate of visual acuity loss among subgroups with different 
NOD2 mutations, it was noted that patients with p.R334W and p.R334Q mutations 
had less visual acuity loss compared to patients with all other genetic variants 
combined (p=0.04, LogRank test). A sub-analysis comparing p.R334W versus 
p.R334Q did not show a significant difference.  
 
 
Discussion 
Ocular involvement is one of the three main clinical features of Blau syndrome. We 
here report data on the ocular phenotype at baseline study visit and present interim 
follow-up data from the first multicenter, international prospective case series on the 
evolution of Blau uveitis in 50 patients. To the best of our knowledge, and based on 
computerized literature search, our case series represents the largest group of 
patients prospectively studied. We found that active anterior and posterior uveitis 
persists over time in more than half of the patients despite combined topical and 
systemic therapy. In this group, there was a high rate of ocular complications 
(macular edema, raised intraocular pressure and cataract) alongside a progressive 
decrease in visual acuity. More than 25% of patients suffered moderate to severe 
visual impairment. Our findings confirm the high morbidity of Blau syndrome uveitis, 
as previously described 5,7,11,12,13.  
The hallmark finding in Blau syndrome uveitis is a chronic bilateral panuveitis with 
multifocal chorioretinal lesions and our prospective study showed that more than half 
of patients had panuveitis at baseline visit, and particularly more frequently in 
patients with a longer disease duration (p=0.01, simple logistic regression). These 
results confirm in a more robust data set and data capture findings from previous 
studies with panuveitis ranging from 33% to 94% dependent on the study 2,6,7.  
Recently, a detailed study on 17 eyes showed a distinctive nodular peripapillary 
appearance in 76% of eyes, alongside chronic bilateral panuveitis. It was postulated 
that these peripapillary nodular excrescences could be related to granulomatous 
inflammation at the level of the optic nerve head7.  Another prior study showed 
peripapillary granulomas to be present in one patient14. However this series shows 
that optic disc abnormalities were only noted in 39% of patients at baseline, ranging 
from optic nerve head pallor, edema and only in 12% of eyes were peripapillary 
nodules noted. Of note: there may be an underestimate of the prevalence of optic 
nerve findings as study methodology did not require fundus photographs and reading 
centre assessment.    
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Patients with Blau syndrome may be misdiagnosed initially as juvenile idiopathic 
arthritis (JIA). Although both diseases show some overlapping features, there are 
clear distinctions in uveitis phenotype, severity of inflammation and ocular disease 
progression. On comparing the data from our study with patients with JIA-uveitis, a 
number of differences are illuminated 15, 16, 17. For example, uveitis is seen in 10-20% 
of JIA patients, and almost exclusively involves the anterior segment. In our Blau 
patients, uveitis was seen in 76% of patients with frequent intermediate and posterior 
involvement. Although complications of anterior eye involvement in JIA are not 
uncommon, the long-term outcome of visual function has a better prognosis. In a 
study of more than 1000 JIA patients, only 9% of eyes had visual acuity worse than 
0.3 logMAR (Snellen 20/40) after a mean follow-up of 6.3 years15.  In comparison, at 
baseline visit, 27% of the eyes presented with visual acuity worse than 0.3 logMAR 
(20/40). In addition, Blau syndrome is characterized by a persistently active 
panuveitis, which may explain the higher rate of complications leading to more 
cumulative damage and a less favourable visual outcome.  
Our study also highlights the variety and extent of therapies among centers, which is 
not unexpected given the lack of international therapeutic guidelines and evidence of 
therapeutic effectivity in Blau uveitis. Although currently we only have interim follow-
up data alongside the retrospective data collection, including treatment and duration 
of uveitis and extent of uveitis at baseline assessment, we note a high prevalence of 
persistent uveitis activity despite systemic steroid, immune modulating and biologic 
treatments. An interesting observation is the possible value of IL-1 inhibition in 
treatment resistant Blau syndrome 6, 14. One of these patients is included in the 
current series.    
Okafuji et al suggested an association between visual impairment and the 2 most 
frequent NOD2 genotypes18. In our study, patients with these p.R334W or p.R334Q 
genotypes had a significantly slower rate of visual acuity loss compared to other 
mutations combined. A sub-analysis of p.R334W versus p.R334Q did not reach 
statistical significance. The role of NOD2 genotyping to predict visual outcome in 
patients with Blau syndrome is still unclear. 
We acknowledge that the study design imposed limits in the degree of detail in the 
description of the Blau syndrome ocular phenotype. A standardized data collection 
form (available as supplemental material from AJO.com) was used; we relied on the 
expert judgment of the local ophthalmologists to complete this. Because no 
standardized description variables were used to describe specific fundus changes, 
information on some phenotypic details may have been lost. Our study included only 
yearly visits, thereby precluding the recording of possible intra-year fluctuations. The 
high rates of active ocular inflammation observed at the yearly evaluations however, 
are consistent with an unrelenting and unremitting pattern in Blau uveitis. Imaging 
techniques to assess posterior eye disease and optic nerve involvement are evolving 
rapidly, but were not widely available at the time of study design (2010) and so not 
included in this study. Additional imaging examinations in a future study will be of 
interest to even better define phenotypic details of Blau uveitis. For statistical 
analysis, we did not consider clustering within families, due to the small sample size, 
although data collection for this study is still ongoing and full 5-year data will be 
reported duly. Notwithstanding, this study provides cross-sectional data and 
importantly, interim follow-up analysis given the prevalence of on-going inflammation. 
The data at this stage demonstrate that uveitis activity, complications and visual 
acuity loss are persistent.   
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In conclusion, Blau syndrome is associated with severe ocular morbidity. Ophthalmic 
features in the classical triad are usually the last to manifest. Our findings further 
demonstrate that despite maximal local treatment and additional systemic 
immunosuppression (albeit varied between centers), disease activity is insufficiently 
controlled in this group. Advances in the understanding of downstream effects of 
NOD2 mutations will likely contribute to the development of effective targeted 
therapies. 
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Figure captions 
 
Figure 1 :  
Fundus pictures showing features of Blau Syndrome uveitis.  Pictures on the 
top show the right eye of a Blau patient with panuveitis. Pictures on the bottom 
show the left eye of a different Blau patient with panuveitis.   
Top left: Widefield fundus picture of right eye, showing multiple chorioretinal scars in 
the inferior retina. The optic disc is pale and has a nodular border, more detailed in 
the top right picture.   
Top right: Optic disc fundus picture of right eye, showing a pale optic disc with a 
nodular border and inferior chorioretinal scars.  
Bottom left: Widefield fundus picture of the left eye showing 
multiple chorioretinal scars and a nodular border around the optic disc,   
Bottom right: Optic disc fundus picture of left eye, showing peripapillary nodules 
around the border of the optic disc. Multiple chorioretinal scars and a macular scar 
are also visible.  
(courtesy of dr C. Guly, Bristol Eye Hospital, Bristol UK) 
 
Figure 2 : 
Evolution of inflammatory features in Blau uveitis at baseline and during 
follow-up. Data are expressed as percentages of eyes with ocular involvement (75 
eyes at baseline, 47 eyes at year 1, 30 eyes at year 2, and 18 eyes at year 3). 
Presence of AC cells was defined as grade ≥ 0.5 and AC flare as grade ≥1 according 
to SUN classification; vitreous haze as grade ≥1 according 
to Nussenblatt classification. AC: anterior chamber. 
 
Figure 3:  
Visual acuity loss in Blau uveitis during disease course.               
Kaplan Meier regression analysis for the best eye showing survival rates of 0.9, 0.8 
and 0.67, after 1, 2 and 3 years of follow-up, respectively. In a sub-analysis, the rate 
of visual acuity loss proved to be significantly lower in patients with R334W or R334Q 
mutation (survival rates of 0.97, 0.9 and 0.72), compared to patients with all other 
mutations combined (survival rates of 0.7 and 0.5, no year 3 data available) (p=0.04). 
 
 
 
